Clinical utility of the 21-gene Oncotype DX® Recurrence Score® (RS) assay in hormone receptor-positive, HER2-negative breast cancer (BC)

The Breast ◽  
2017 ◽  
Vol 32 ◽  
pp. S97
Author(s):  
A. Lau ◽  
D. Miller ◽  
D. Davison ◽  
M. Rothney ◽  
P. Borgen
Sign in / Sign up

Export Citation Format

Share Document